Anebulo Pharmaceuticals, Inc. (ANEB) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Anebulo Pharmaceuticals, Inc. (ANEB) Healthcare & Pipeline Overview

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in treatments for cannabinoid intoxication and substance addiction. Their primary focus is ANEB-001, a cannabinoid receptor antagonist designed to counter the effects of cannabinoid overdose, positioning them in a niche market within the broader biotechnology landscape.

What Is the Investment Thesis for ANEB?

Anebulo Pharmaceuticals presents a focused investment opportunity within the biotechnology sector, centered around ANEB-001, a cannabinoid receptor antagonist targeting cannabinoid intoxication. The increasing prevalence of cannabis use, coupled with the potential for acute intoxication, creates a market need for effective treatments. Successful clinical trials and subsequent FDA approval of ANEB-001 could drive significant value. However, the company's financial viability is contingent on securing additional funding to support ongoing research and development. The current market capitalization of $13.4M reflects the early stage of the company and the inherent risks associated with biotechnology investments. Key catalysts include the progression of ANEB-001 through clinical trials and potential partnerships for commercialization. Investors should closely monitor clinical trial results and regulatory developments to assess the company's prospects.

Based on FMP financials and quantitative analysis

ANEB Key Highlights

• Lead product candidate ANEB-001 targets a growing market need for treatments related to cannabinoid intoxication.
• The company operates with a lean team of 2 employees, reflecting a focused approach to drug development.
• Anebulo Pharmaceuticals is a clinical-stage company, indicating potential for significant value creation upon successful clinical trial outcomes.
• The company's market capitalization is $0.02B, reflecting its early stage and associated risks.
• Beta of -0.70 suggests a potential inverse correlation with the broader market, which may offer diversification benefits.

Who Are ANEB's Competitors?

ANEB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANEB's Key Strengths?

• Focused on a specific and growing market need (cannabinoid intoxication).
• Lead product candidate (ANEB-001) with a clear mechanism of action.
• Relatively new company, allowing for agility and adaptability.
• Strong intellectual property potential with ANEB-001.

What Are ANEB's Weaknesses?

• Limited financial resources.
• Small team size.
• Reliance on a single product candidate.
• Early-stage company with limited track record.

What Could Drive ANEB Stock Higher?

• Phase 2 clinical trial results for ANEB-001 in treating cannabinoid intoxication.
• Potential FDA discussions regarding the regulatory pathway for ANEB-001.
• Securing additional funding to support clinical development and operations.

What Are the Key Risks for ANEB?

• Financial-distress signal — its Altman Z-Score of -7.74 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-74.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials for ANEB-001.
• Delays or rejection in obtaining regulatory approval from the FDA.
• Competition from other companies developing treatments for substance abuse.
• Dependence on a single product candidate (ANEB-001).
• Limited financial resources to support ongoing research and development.

What Are the Growth Opportunities for ANEB?

• Growth opportunity 1: Successful clinical development and FDA approval of ANEB-001 represents a significant growth opportunity for Anebulo Pharmaceuticals. The market for cannabinoid intoxication treatments is nascent but growing, driven by the increasing prevalence of cannabis use. Positive clinical trial results could lead to rapid market adoption and revenue generation. The timeline for this opportunity is dependent on the successful completion of ongoing and future clinical trials, with potential for commercialization within the next 3-5 years.
• Growth opportunity 2: Strategic partnerships with pharmaceutical companies or other biotechnology firms could accelerate the development and commercialization of ANEB-001. Collaborations could provide access to additional funding, expertise, and distribution channels. This opportunity could materialize in the near term, as Anebulo Pharmaceuticals seeks to expand its resources and capabilities. The potential market size would depend on the terms of the partnership and the scope of the collaboration.
• Growth opportunity 3: Expansion of ANEB-001's application to treat other cannabinoid-related conditions represents a potential growth avenue. The drug's mechanism of action as a cannabinoid receptor antagonist could be applicable to a broader range of indications beyond acute intoxication. This opportunity would require further research and development, but could significantly expand the market potential for ANEB-001 in the long term.
• Growth opportunity 4: Geographic expansion into international markets represents another growth opportunity for Anebulo Pharmaceuticals. As cannabis legalization spreads globally, the need for cannabinoid intoxication treatments will likely increase in other countries. This opportunity would require navigating different regulatory environments and establishing distribution networks in new markets. The timeline for international expansion would depend on regulatory approvals and market conditions in each target country.
• Growth opportunity 5: Development of additional products targeting substance addiction represents a longer-term growth opportunity for Anebulo Pharmaceuticals. Leveraging its expertise in cannabinoid pharmacology, the company could expand its pipeline to include treatments for other forms of substance abuse. This would diversify the company's revenue streams and reduce its reliance on ANEB-001. The timeline for this opportunity would depend on the availability of funding and the progress of research and development efforts.

What Opportunities Does ANEB Have?

• Increasing prevalence of cannabis use and related intoxication incidents.
• Potential for strategic partnerships with larger pharmaceutical companies.
• Expansion into international markets.
• Development of additional products targeting substance addiction.

What Threats Does ANEB Face?

• Regulatory hurdles and potential delays in FDA approval.
• Competition from other companies developing treatments for substance abuse.
• Uncertainty surrounding the long-term effects of cannabis use.
• Potential for generic competition if ANEB-001's patent protection is weak.

What Are ANEB's Competitive Advantages?

• Proprietary drug candidate (ANEB-001) with patent protection.
• Specialized focus on cannabinoid intoxication, a niche market.
• Clinical-stage development with potential for first-mover advantage.
• Expertise in cannabinoid pharmacology.

What Does ANEB Do?

Anebulo Pharmaceuticals, Inc., established in 2020 and based in Lakeway, Texas, is a clinical-stage biotechnology company dedicated to developing and commercializing treatments for individuals suffering from acute cannabinoid intoxication and substance addiction. The company's core focus is on addressing the growing need for effective interventions related to cannabinoid use. Their lead product candidate, ANEB-001, is a small molecule cannabinoid receptor antagonist engineered to reverse the effects of cannabinoid intoxication and overdose. ANEB-001 represents a targeted approach to counteracting the psychoactive effects of cannabinoids, potentially mitigating the adverse consequences associated with excessive consumption. As a relatively new entrant in the biotechnology sector, Anebulo Pharmaceuticals is currently navigating the clinical trial process to validate the safety and efficacy of ANEB-001. The company's future success hinges on the successful completion of these trials and subsequent regulatory approvals, which would pave the way for commercialization and market penetration. Anebulo Pharmaceuticals operates with a lean team, emphasizing a focused and agile approach to drug development. Their strategic focus on cannabinoid intoxication positions them within a rapidly evolving landscape, influenced by changing regulations and societal attitudes towards cannabis use.

What Products and Services Does ANEB Offer?

• Develop treatments for acute cannabinoid intoxication.
• Focus on substance addiction treatments.
• Research and develop small molecule cannabinoid receptor antagonists.
• Conduct clinical trials to evaluate the safety and efficacy of ANEB-001.
• Seek regulatory approval for ANEB-001 from relevant authorities.
• Commercialize approved treatments for cannabinoid intoxication and substance addiction.

How Does ANEB Make Money?

• Develop and patent novel pharmaceutical products.
• Conduct clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from agencies like the FDA.
• Commercialize and market approved drugs, potentially through partnerships.

What Industry Does ANEB Operate In?

Anebulo Pharmaceuticals operates within the biotechnology industry, specifically targeting the emerging market for treatments related to cannabinoid intoxication. The increasing legalization and social acceptance of cannabis have led to a rise in cannabis use, and consequently, a greater incidence of acute intoxication. This trend creates a demand for effective interventions like ANEB-001. The competitive landscape includes companies developing treatments for substance abuse and related conditions. However, Anebulo Pharmaceuticals' focus on cannabinoid intoxication provides a degree of differentiation. The overall biotechnology industry is characterized by high risk and high reward, with significant investments required for research and development, clinical trials, and regulatory approvals.

Who Are ANEB's Key Customers?

• Individuals experiencing acute cannabinoid intoxication.
• Healthcare providers treating patients with cannabinoid intoxication.
• Hospitals and emergency rooms managing cannabinoid-related emergencies.
• Substance abuse treatment centers.

Company Profile

Anebulo Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lakeway, US. The company is led by CEO Richard Anthony Cunningham. ANEB has traded publicly since 2021.

F-Score 1/9Financial Health

Anebulo Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.74 places it in the distress zone, a signal of elevated financial risk.

ROE -75%Key Financial Metrics

Return on equity for Anebulo Pharmaceuticals, Inc. stands at -74.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -84.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 16.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -41.3%, the inverse of the P/E and a quick read on earnings relative to price.

ANEB Valuation & Market Position

With a $13.4M market cap, Anebulo Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ANEB's quantitative score of 48/100 is below the peer average of 73/100.

FY2026 estForward Outlook

Wall Street analysts project Anebulo Pharmaceuticals, Inc. revenue of about $16.8M for fiscal 2026, with EPS near $-0.48.

ANEB Financials

ANEB Latest News

ANEB Analyst Consensus

ANEB MoonshotScore

ANEB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources